Biochemical markers subtyping major depressive disorder
Open accessThe DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.
Abstract
The pathophysiology of major depressive disorder (MDD) remains elusive, and there is no established biochemical marker used in the daily clinical setting. This situation may result in part from the heterogeneity of MDD, which might include heterogeneous subgroups with different biological mechanisms. In this review, we discuss three promising biological systems/markers to potentially subtype MDD: the dopamine system, the hypothalamic–pituitary–adrenal axis, and chronic inflammatory markers. Several lines of evidence suggest that a facet of MDD is a dopamine agonist‐responsive subtype. Focusing on the hypothalamic–pituitary–adrenal axis, depressive spectrum disorders show hypercortisolism to hypocortisolism, which could be detected by hormonal challenge tests, such as the dexamethasone/corticotrophin‐releasing hormone test. Finally, accumulating evidence suggests that at least some MDD patients show characteristics similar to those of chronic inflammatory diseases, including neuroinflammatory markers and reduced tryptophan due to the increased activation of the tryptophan–kynurenine pathway. Future studies should examine the inter‐relations between these systems/markers to subtype and integrate the pathophysiology of MDD.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Lopez, A. D., Mathers, C. D., Ezzati, M., Jamison, D. T., & Murray, C. J. (2006) · The Lancet · doi:10.1016/s0140-6736(06)68770-9 · Cited by 5,630
A psychobiological model of temperament and character
Cloninger, C. R. (1993) · Archives of General Psychiatry · doi:10.1001/archpsyc.1993.01820240059008 · Cited by 5,458
Folkman, S., & Lazarus, R. S. (1985) · Journal of Personality and Social Psychology · doi:10.1037/0022-3514.48.1.150 · Cited by 4,845
A Meta-Analysis of Cytokines in Major Depression
Dowlati, Y., Herrmann, N., Swardfager, W., Liu, H., Sham, L., Reim, E. K., & Lanctôt, K. L. (2010) · Biological Psychiatry · doi:10.1016/j.biopsych.2009.09.033 · Cited by 4,729
The Hopkins Symptom Checklist (HSCL): A self-report symptom inventory
Derogatis, L. R., Lipman, R. S., Rickels, K., Uhlenhuth, E. H., & Covi, L. (1974) · Behavioral Science · doi:10.1002/bs.3830190102 · Cited by 4,604
Inflammation and Its Discontents: The Role of Cytokines in the Pathophysiology of Major Depression
Miller, A. H., Maletic, V., & Raison, C. L. (2009) · Biological Psychiatry · doi:10.1016/j.biopsych.2008.11.029 · Cited by 3,848 · cited 2×
“and AVP, development of glucocorticoid resistance, activation of indoleamine 2,3-dioxygenase (IDO), and increased expression of serotonin transporter.(81,85) Among them, the activation of IDO has received much attention as it potentially synthesizes the inflammation hypothesis, serotonin hypothesis, and the HPA axis a…”
BackgroundAssociations of depression with C-reactive protein, IL-1, and IL-6: a meta-analysis.
Howren, M. B., Lamkin, D. M., & Suls, J. (2009) · Psychosomatic Medicine · doi:10.1097/psy.0b013e3181907c1b · Cited by 2,766
Cross-national epidemiology of major depression and bipolar disorder
Weissman, M. M. (1996) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1996.03540040037030 · Cited by 2,302
Nemeroff, C. B., Widerlöv, E., Bissette, G., Walléus, H., Karlsson, I., Eklund, K., Kilts, C. D., Loosen, P. T., & Vale, W. (1984) · Science · doi:10.1126/science.6334362 · Cited by 1,485
The role of dopamine in the pathophysiology of depression
Dunlop, B. W., & Nemeroff, C. B. (2007) · Archives of General Psychiatry · doi:10.1001/archpsyc.64.3.327 · Cited by 1,244 · cited 1×
“As dopamine, particularly that of the mesolimbic system, plays a central role in regulating motivation, psychomotor speed, concentration and emotions like pleasure, it is postulated that at least some of the treatment-resistant patients are in a hypodopaminergic state where medications such as dopamine reuptake inhibi…”
Background
Cited by
Biomarkers for depression: recent insights, current challenges and future prospects
Strawbridge, R., Young, A. H., & Cleare, A. J. (2017) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s114542 · Cited by 415
Mac Giollabhui, N., Ng, T. H., Ellman, L. M., & Alloy, L. B. (2021) · Molecular Psychiatry · doi:10.1038/s41380-020-00867-4 · Cited by 361
Peripheral Markers of Depression
Nobis, A., Zalewski, D., & Waszkiewicz, N. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9123793 · Cited by 197
The role of depressive subtypes within the neuroinflammation hypothesis of major depressive disorder
Woelfer, M., Kasties, V., Kahlfuss, S., & Walter, M. (2019) · Neuroscience · doi:10.1016/j.neuroscience.2018.03.034 · Cited by 171
Matsuno, H., Tsuchimine, S., O’Hashi, K., Sakai, K., Hattori, K., Hidese, S., Nakajima, S., Chiba, S., Yoshimura, A., Fukuzato, N., et al. (2022) · Molecular Psychiatry · doi:10.1038/s41380-022-01618-3 · Cited by 164
Self-citationMetabolomic and inflammatory signatures of symptom dimensions in major depression
Brydges, C. R., Bhattacharyya, S., Dehkordi, S. M., Milaneschi, Y., Penninx, B., Jansen, R., Kristal, B. S., Han, X., Arnold, M., Kastenmüller, G., et al. (2022) · Brain, Behavior, and Immunity · doi:10.1016/j.bbi.2022.02.003 · Cited by 108
Biomarkers of post-covid depression
Lorkiewicz, P., & Waszkiewicz, N. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10184142 · Cited by 102
Kato, T. A., Hashimoto, R., Hayakawa, K., Kubo, H., Watabe, M., Teo, A. R., & Kanba, S. (2016) · Psychiatry and Clinical Neurosciences · doi:10.1111/pcn.12360 · Cited by 86
“has recently proposed a classification of depression focusing on the HPA axis functions.(64) Interestingly, a recent clinical research regarding atypical depression has suggested a significantly higher comorbidity with metabolic syndrome.”
BackgroundKuwano, N., Kato, T. A., Setoyama, D., Sato-Kasai, M., Shimokawa, N., Hayakawa, K., Ohgidani, M., Sagata, N., Kubo, H., Kishimoto, J., et al. (2018) · Journal of Affective Disorders · doi:10.1016/j.jad.2018.01.014 · Cited by 69
“Biomarkers for MDD have been investigated by various research methods including brain imaging (Gadad et al., 2017; Gururajan et al., 2016; Kunugi et al., 2015).”
Blood biomarkers of Hikikomori, a severe social withdrawal syndrome
Hayakawa, K., Kato, T. A., Watabe, M., Teo, A. R., Horikawa, H., Kuwano, N., Shimokawa, N., Sato-Kasai, M., Kubo, H., Ohgidani, M., et al. (2018) · Scientific Reports · doi:10.1038/s41598-018-21260-w · Cited by 69
Bias in Peripheral Depression Biomarkers
Carvalho, A. F., Köhler, C. A., Brunoni, A. R., Miskowiak, K. W., Herrmann, N., Lanctôt, K. L., Hyphantis, T. N., Quevedo, J., Fernandes, B. S., & Berk, M. (2016) · Psychotherapy and Psychosomatics · doi:10.1159/000441457 · Cited by 52
Pathophysiology of Major Depression by Clinical Stages
de Menezes Galvão, A. C., Almeida, R. N., de Sousa, G. M., Leocadio-Miguel, M. A., Palhano-Fontes, F., de Araujo, D. B., Lobão-Soares, B., Maia-de-Oliveira, J. P., Nunes, E. A., Hallak, J. E. C., et al. (2021) · Frontiers in Psychology · doi:10.3389/fpsyg.2021.641779 · Cited by 31
Mac Giollabhui, N., Alloy, L. B., Schweren, L. J. S., & Hartman, C. A. (2021) · Brain Behavior and Immunity · doi:10.1016/j.bbi.2021.05.022 · Cited by 25
Xie, Z., Gu, W., & Ming, T. (2023) · Combinatorial Chemistry & High Throughput Screening · doi:10.2174/1386207325666220404123433 · Cited by 6
Metadata
- Authors
- Kunugi, H., Hori, H., & Ogawa, S.
- Venue
- Psychiatry and Clinical Neurosciences
- Publisher
- Wiley
- Published
- 2015-05-13
- Volume
- 69
- Issue
- 10
- Pages
- 597-608
- ISSN
- 1323-1316 (ISSN-L)
- 1440-1819
- OpenAlex
- W1578958407
- Cited by
- 114
- References
- 30
- FWCI
- 9.31
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.